| Authors: |
Panteli D; European Observatory on Health Systems and Policies, Brussels, Belgium., Anderson M; Health Organisation, Policy, Economics (HOPE), Centre for Primary Care & Health Services Research, The University of Manchester, Manchester, UK. michael.anderson-3@manchester.ac.uk.; LSE Health, Department of Health Policy, London School of Economics and Political Science, London, UK. michael.anderson-3@manchester.ac.uk., Fieldman T; Department of Clinical Microbiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK., Baraldi E; Department of Business Studies, Uppsala University, Uppsala, Sweden., Tängdén T; Department of Medical Sciences, Uppsala University, Uppsala, Sweden., Vogler S; WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomics Department, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute), Vienna, Austria.; Department of Health Care Management, Technische Universität Berlin, Berlin, Germany., Årdal C; Antimicrobial Resistance Centre, Norwegian Institute of Public Health, Oslo, Norway., Mossialos E; LSE Health, Department of Health Policy, London School of Economics and Political Science, London, UK. |
